Concepedia

Publication | Closed Access

Open clinical studies on a new angiotensin II receptor antagonist, TCV 116.

23

Citations

0

References

1994

Year

Toshio Ogihara, K Arakawa, Osamu Iimura, Kaito Abe, T Saruta, Masakazu Ishii, K Hiwada, M Fujishima, Koshiro Fukiyama
PubMed

Abstract

TCV 116, an angiotensin II receptor antagonist, has potential as an antihypertensive agent. A dose of 4-8 mg once per day appears to be appropriate for the treatment of patients with mild to moderate essential hypertension.